14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $225.62 $260.34 Thursday, 2nd May 2024 UTHR stock ended at $258.13. This is 1.17% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 2.47% from a day low at $254.06 to a day high of $260.34.
90 days $208.62 $260.34
52 weeks $204.44 $261.48

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Mar 10, 2016 $125.22 $127.85 $121.92 $122.61 519 400
Mar 09, 2016 $125.19 $125.19 $121.37 $123.97 595 000
Mar 08, 2016 $131.38 $133.69 $124.50 $124.80 608 200
Mar 07, 2016 $127.00 $133.69 $125.26 $131.87 614 700
Mar 04, 2016 $126.00 $129.72 $124.10 $127.64 658 800
Mar 03, 2016 $128.48 $129.64 $124.97 $126.00 833 700
Mar 02, 2016 $126.94 $129.04 $125.74 $128.88 647 800
Mar 01, 2016 $122.14 $127.09 $121.84 $126.54 832 900
Feb 29, 2016 $123.01 $127.31 $121.54 $121.94 880 200
Feb 26, 2016 $125.83 $128.85 $120.50 $123.80 931 100
Feb 25, 2016 $128.75 $129.00 $119.05 $124.83 901 900
Feb 24, 2016 $126.26 $130.37 $124.56 $129.17 707 900
Feb 23, 2016 $128.20 $130.82 $127.48 $127.73 488 100
Feb 22, 2016 $128.37 $130.51 $126.98 $128.13 689 500
Feb 19, 2016 $128.49 $128.67 $123.50 $127.32 1 056 000
Feb 18, 2016 $132.00 $133.22 $126.60 $127.89 838 500
Feb 17, 2016 $130.45 $133.84 $129.01 $131.62 526 600
Feb 16, 2016 $128.40 $131.39 $127.58 $129.83 860 300
Feb 12, 2016 $124.18 $128.20 $121.71 $126.56 727 400
Feb 11, 2016 $117.79 $122.85 $117.08 $121.61 820 500
Feb 10, 2016 $120.83 $126.08 $119.59 $119.74 706 700
Feb 09, 2016 $114.96 $121.20 $113.20 $119.32 614 500
Feb 08, 2016 $116.82 $119.75 $114.50 $115.75 906 100
Feb 05, 2016 $121.20 $122.55 $116.60 $118.45 1 180 500
Feb 04, 2016 $121.87 $125.98 $119.80 $122.75 665 100
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT